Literature DB >> 11090946

Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity.

B K Park1, N R Kitteringham, H Powell, M Pirmohamed.   

Abstract

Idiosyncratic drug toxicity is a major complication of drug therapy and drug development. Such adverse drug reactions (ADRs) include anaphylaxis, blood dyscrasias, hepatotoxicity and severe cutaneous reactions. They are usually serious and can be fatal. At present, prediction of idiosyncratic ADRs at the preclinical stage of drug development is not possible because there are no suitable animal models and we do not understand the basic mechanisms involved in the toxicity when it does occur in man. Many idiosyncratic reactions appear to have an immunological aetiology. For example, there is increasing evidence for the role of T lymphocytes in severe skin reactions. Nevertheless, the sequence of events by which a simple chemical can elicit severe tissue damage remains poorly understood and alternative novel mechanisms of toxicity must also be explored. The purpose of this article will be to review the currently accepted mechanisms of idiosyncratic drug toxicity at the chemical and the molecular levels. In particular, we will consider how recent advances in cellular immunology and molecular biology can improve our understanding of both the chemical and clinical aspects of drug hypersensitivity. Recent advances in the role of both inter- and intra-cellular signalling in the regulation of the immune response to drugs and their metabolites will be discussed. The long-term aim of such research is to provide test systems for the evaluation of drug safety and patient susceptibility to idiosyncratic drug toxicity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11090946     DOI: 10.1016/s0300-483x(00)00303-6

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  14 in total

Review 1.  Drug Adverse Reaction Target Database (DART) : proteins related to adverse drug reactions.

Authors:  Zhi Liang Ji; Lian Yi Han; Chun Wei Yap; Li Zhi Sun; Xin Chen; Yu Zong Chen
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 2.  The art and science of risk management: a US research-based industry perspective.

Authors:  Janice K Bush; Wanju S Dai; Gretchen S Dieck; Linda S Hostelley; Thomas Hassall
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  The combination of nuclear and mitochondrial mutations as a risk factor for idiosyncratic toxicity.

Authors:  Daria LaRocca; David F Lehmann; Andras Perl; Takayuki Ozawa; Peter D Holohan
Journal:  Br J Clin Pharmacol       Date:  2006-08-30       Impact factor: 4.335

4.  The Opportunities of Metabolomics in Drug Safety Evaluation.

Authors:  Pengcheng Wang; Amina I Shehu; Xiaochao Ma
Journal:  Curr Pharmacol Rep       Date:  2017-01-03

Review 5.  Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin.

Authors:  Sanjoy Roychowdhury; Craig K Svensson
Journal:  AAPS J       Date:  2005-12-09       Impact factor: 4.009

6.  Bioactivation, protein haptenation, and toxicity of sulfamethoxazole and dapsone in normal human dermal fibroblasts.

Authors:  Payal Bhaiya; Sanjoy Roychowdhury; Piyush M Vyas; Mark A Doll; David W Hein; Craig K Svensson
Journal:  Toxicol Appl Pharmacol       Date:  2006-04-17       Impact factor: 4.219

Review 7.  Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide.

Authors:  Urs A Boelsterli
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 8.  Biomarkers, metabonomics, and drug development: can inborn errors of metabolism help in understanding drug toxicity?

Authors:  Subrahmanyam Vangala; Alfred Tonelli
Journal:  AAPS J       Date:  2007-07-20       Impact factor: 4.009

Review 9.  Clinical pharmacology: special safety considerations in drug development and pharmacovigilance.

Authors:  Kwame N Atuah; Dyfrig Hughes; Munir Pirmohamed
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  Recurrent acute thrombocytopenia in the hospitalized patient: sepsis, DIC, HIT, or antibiotic-induced thrombocytopenia.

Authors:  Talla A Rousan; Ibrahim T Aldoss; Benjamin D Cowley; Brian R Curtis; Daniel W Bougie; Richard H Aster; James N George
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.